Two medications. Both injectable. Both producing impressive results in clinical trials. Both becoming household names in a way that very few prescription protocols ever do. And both frequently confused with each other.
They are related but they are not the same. The difference is meaningful and it affects who each one is best suited for.
Semaglutide — the GLP-1 agonist
Semaglutide works on a single receptor: the GLP-1 receptor. It mimics the natural GLP-1 hormone your gut produces after eating - amplifying the fullness signal, reducing appetite, slowing gastric emptying, and improving insulin sensitivity.
The clinical trial results for semaglutide - the STEP trials - showed average weight loss of approximately 14–15% of body weight over 68 weeks in non-diabetic participants. For a person starting at 200 pounds, that is 28–30 pounds.
Tirzepatide — the dual agonist
Tirzepatide works on two receptors simultaneously: GLP-1 and GIP — glucose-dependent insulinotropic polypeptide. GIP is a second gut hormone involved in insulin regulation and, separately, in how the body stores and burns fat.
The dual mechanism appears to produce greater effects. The SURMOUNT trials showed average weight loss of 20–22% of body weight over 72 weeks — meaningfully higher than semaglutide in head-to-head comparisons.
More is not always better for every person. The right protocol is the one your provider recommends for your specific metabolic picture — not the one with the highest average trial number.
Side effect profile
Both medications share a similar side effect profile. Nausea, particularly early in the dose titration period, is the most common. It typically improves significantly within the first two to four weeks as the body adjusts. Starting at lower doses and titrating upward reduces this considerably.
Tirzepatide's nausea profile is generally reported as comparable to or slightly milder than semaglutide at equivalent efficacy levels, though this varies individually.
The cost question
Compounded semaglutide and tirzepatide are significantly less expensive than brand-name versions. At Empathetix, compounded protocols start at $114.55/month for semaglutide and $150.91/month for tirzepatide on prepaid plans.
The brand-name products — Ozempic, Wegovy, Mounjaro, Zepbound — often cost $900–$1,400/month without insurance. Compounded versions use the same active compound formulated by a 503A pharmacy.
Important: Compounded semaglutide and tirzepatide are not FDA-approved finished drug products. They are compounded by a licensed 503A pharmacy pursuant to individual patient prescriptions and have not undergone FDA review as finished products.
Which one is right for you?
Your provider makes this determination based on your health history, prior medication experience, metabolic markers from your lab panel, and clinical judgment. This is a conversation to have, not a decision to make from a comparison article.
Ready to find out if a GLP-1 program is right for you?
The consultation is always free. A licensed provider
reviews your profile and gives you a straight clinical
answer - no commitment required. You only pay if a
protocol is approved for your situation.
Start with a free conversation →
Free consultation · Provider review within 24 hours ·
Ships in 2 days if approved
For informational purposes only — not medical advice. Results vary and are not guaranteed. All protocols require provider evaluation and approval before
anything is prescribed. Compounded medications are not FDA-approved finished drug products. Not all patients will be approved for treatment. Medical emergency? Call 911.
© Empathetix Wellness · empathetix.com ·
(801) 804-3166 · info@empathetix.com